Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, March 11, 2020
HitGen and Kaken Pharmaceutical have entered into a license agreement to develop a novel class of drugs.
read more
In Sisseln, Switzerland, high-quality tablets, granules, effervescent tablets and hard capsules are produced by Aenova on a footprint of more than 6,000 m2 and a production area of more than 1,900 m2 by 160 employees - and with a completely CO2-free ...
read more
Wednesday, March 17, 2021
HomTex has received EUA for its Level 1 Surgical masks, greenlighting their entry into the US government and medical PPE markets.
read more
Hongene Biotech Corporation announced its role in advancing DNV001, a novel GalNAc-conjugated siRNA targeting dyslipidemia. The therapy, developed by Hangzhou Dingle Xinwei Biotechnology, recently received investigational new drug (IND) clearance ...
read more
Monday, September 09, 2024
Hongene Biotech Corporation, a nucleic acid manufacturing company, and ReciBioPharm, an advanced therapeutics CDMO services provider, have announced a strategic collaboration that will enhance gene editing drug manufacturing capabilities.
read more
Hongene has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle (LNP) drug delivery, to its scientific advisory board. This strategic addition reinforces Hongene’s commitment to advancing RNA therapeutics.
read more
Hongene Biotech Corporation entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use.
read more
Wednesday, January 02, 2019
HOOKIPA Pharma announced that it has achieved its first research milestone in its collaboration and license agreement with Gilead Sciences.
read more
Horizon Discovery Group announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines.
read more
Horizon Discovery Group announced its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases.
read more
Monday, February 12, 2018
Horizon Discovery Group announces that it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer.
read more
Horizon Discovery Group announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.
read more
Tuesday, January 21, 2020
Horizon Discovery Group will license its gene-edited Glutamine Synthetase knockout CHO K1 cell line to NGM Biopharmaceuticals.
read more
Monday, November 17, 2014
Horizon Discovery Group plc (LSE: HZD) (Horizon), a leading provider of research tools to support translational genomics, , has today announced the formation of a new Scientific Advisory Board (SAB) for its Diagnostics Business Unit (Horizon ...
read more
Horizon Discovery Group has announced the addition of single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio.
read more